Thalassaemia major: The murky story of deferiprone

British Medical Journal

Volumn 328, Issue 7436, 2004, Pages 358-359

  Savulescu, Julian ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT;

BETA THALASSEMIA; BLOOD TRANSFUSION; CAUSE OF DEATH; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; HEART DISEASE; HEMOSIDEROSIS; HUMAN; IRON BLOOD LEVEL; LIVER FIBROSIS; MEDICAL ETHICS; PATIENT COMPLIANCE; PRIORITY JOURNAL; THALASSEMIA MAJOR;

EID: 1242318692     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.328.7436.358     Document Type: Editorial

References (11)

1. Piga A, Gagliotti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-96.
2. Spurgeon D. Trials sponsored by drug companies: review ordered. BMJ 1998;317:618.
3. The Olivieri symposium. J Med Ethics 2004;30:1-52.
4. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-23.
5. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100:1566-9.
6. Cohen AR, Galanello R, Piga R, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone Blood 2003;102:1583-7.
7. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516-20.
8. Brittenham GM, Nathan DG, Olivieri NF, Porter JB, Pippard M, Vichinsky EP, et al. Deferiprone and hepatic fibrosis. Blood 2003;101:5089-90.
9. Viens A, Savulescu J. Introduction to the Olivieri symposium. J Med Ethics 2004;30:1-7.
10. Savulescu J, Spriggs M. The hexamethonium asthma study and the death of a normal volunteer in research. J Med Ethics 2002;28:3-4.
11. Savulescu J. Two deaths and two lessons: Is it time to review the structure and function of research ethics committees? J Med Ethics 2002;28:1-2.